Polyanion Nanocomplexes for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral vectors for nucleic acid delivery, such as polyplexes and lipoplexes, face challenges including high toxicity, difficulty in controlling particle size, and low transfection efficiency due to their positive excess charge and large size, which hinders effective transport into cells and can cause adverse interactions with biological membranes and proteins.
Innovation Solution
The formation of nanocomplexes composed of polyanions and cationic amphiphilic peptides in an equimolar ratio, utilizing cooperative electrostatic and hydrophobic interactions to create stable, small-sized complexes with a defined structure, which can be further modified with spacers or biologically active moieties for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If polyplexes and lipoplexes are used for nucleic acid delivery, then transfection efficiency is improved, but toxicity increases and particle size becomes difficult to control
Solution Approach 1:
The patent changes the charge ratio parameter from positive excess (conventional polyplexes/lipoplexes) to equimolar ratio (1:1), which reduces toxicity while maintaining transfection efficiency. This parameter change transforms the harmful positive charge excess into a balanced charge state that minimizes adverse interactions with biological membranes and proteins.
Solution Approach 2:
The patent uses composite materials by combining polyanions (nucleic acids) with cationic amphiphilic peptides to form nanocomplexes. This composite structure provides both the transfection capability of cationic carriers and the reduced toxicity of equimolar charge ratios, overcoming the limitations of conventional single-material systems.
2Productivity
If polyplexes and lipoplexes are used for nucleic acid delivery, then transfection efficiency is improved, but particle size control becomes difficult
Solution Approach 1:
The patent changes the structural organization parameter from random arrangement to linear/ordered arrangement through equimolar complex formation. This structural parameter change enables precise control of particle size (20-200 nm) while maintaining transfection efficiency, as the linear structures pack more uniformly than random aggregates.
Solution Approach 2:
The patent employs aqueous buffer solutions with controlled ionic strength and pH to regulate nanocomplex formation. These hydraulic conditions enable precise control of particle size during self-assembly, producing uniform nanocomplexes without requiring complex manufacturing processes.
3Reliability
If polyanions are transported into cells, then therapeutic effect is achieved, but cell membrane permeation is hindered by negative charge
Solution Approach 1:
The patent uses cationic amphiphilic peptides as intermediary carriers that temporarily associate with polyanions to form neutral nanocomplexes. These intermediaries enable cell membrane permeation by masking the negative charge, after which the therapeutic polyanion is released inside the cell to exert its therapeutic effect.
Solution Approach 2:
The patent changes the charge state parameter of the nucleic acid complex from negative to neutral through equimolar complexation with cationic peptides. This parameter change enables passive diffusion across the cell membrane while preserving the therapeutic polyanion's function upon intracellular release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These nanocomplexes enable efficient and controlled delivery of nucleic acids and peptides into cells with reduced toxicity and improved bioavailability, minimizing interactions with negatively charged cell components and proteins, thereby enhancing therapeutic efficacy while preventing systemic side effects.
Implementation Method 1
utilizing cooperative electrostatic and hydrophobic interactions to create stable, small-sized complexes
Implementation Method 2
utilizing cooperative electrostatic and hydrophobic interactions to create stable, small-sized complexes
Data Source
AI summary
The invention relates to nanocomplexes of polyanions and cationic peptides, which are suitable, for example, for the transport of drugs into cells and the controlled release of said drugs in the organism, and to a complex material in which the nanocomplexes are bonded to a biologically active unit for the selective recognition of tissues, cells, or organelles.